divesiran (SLN124)

News alerts, weekly reports and conference planners

Company:

Silence Therap

Drug class:

TMPRSS6 inhibitor

‹

›

2ms

SANRECO: Study to Assess SLN124 in Patients With Polycythemia Vera (clinicaltrials.gov)

P1/2, N=69, Active, not recruiting, Silence Therapeutics plc | Recruiting --> Active, not recruiting | Trial completion date: Jun 2025 --> Mar 2030 | Trial primary completion date: Dec 2024 --> Sep 2026

2 months ago

Enrollment closed • Trial completion date • Trial primary completion date

divesiran (SLN124)

2years

GEMINI II: A Study Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124 in Adults With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome (clinicaltrials.gov)

P1, N=44, Completed, Silence Therapeutics plc | Active, not recruiting --> Completed | Trial completion date: Sep 2023 --> May 2023

2 years ago

Trial completion • Trial completion date

divesiran (SLN124)

over2years

SLN124, a GalNAc conjugated 19-mer siRNA targeting tmprss6, reduces plasma iron and increases hepcidin levels of healthy volunteers. (PubMed, Am J Hematol)

In all SLN124 groups, a dose-related effect was observed across iron metabolism markers, and across erythroid markers, SLN124 resulted in increased plasma hepcidin levels, peaking around Day 29, and consequent dose-related sustained reductions in plasma iron and transferrin saturation with decreased reticulocyte production, MCHC, and MCV. Results suggest duration of action lasting up to 56 days after a single SLN124 dose, on hepcidin and hematological parameters of iron metabolism (serum iron and TSAT).

over 2 years ago

Journal

divesiran (SLN124)